The nature of the attenuation of Salmonella typhimurium strains expressing human papillomavirus type 16 virus-like particles determines the systemic and mucosal antibody responses in nasally immunized mice

Infection and Immunity

Volumn 67, Issue 7, 1999, Pages 3674-3679

  Benyacoub, Jalil ^a   Hopkins, Sally ^b   Potts, Alexandra ^a   Kelly, Sandra ^c   Kraehenbuhl, Jean Pierre ^b   Curtiss III, Roy ^c   De Grandi, Pierre ^a   Nardelli Haefliger, Denise ^a,d  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d c/o Institut de Microbiologie ^*  (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIGEN; SALMONELLOSIS VACCINE;

ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM; VIRUS ATTENUATION; VIRUS EXPRESSION; VIRUS PARTICLE; WART VIRUS;

EID: 0033008860     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.67.7.3674-3679.1999     Document Type: Article

References (46)

1. Balmelli, C., R. Roden, A. Potts, J. Schiller, P. De Grandi, and D. Nardelli-Haefliger. 1998. Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. J. Virol. 72:8220-8229.
2. Black, R. E., M. M. Levine, M. L. Clements, G. Losonsky, D. Herrington, S. Berman, and S. B. Formal. 1987. Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine. J. Infect. Dis. 155:1260-1265.
3. Bosch, F. X., M. M. Manos, N. Munoz, M. Sherman, A. M. Jansen, J. Peto, M. H. Schiffman, V. Moreno, R. Kurman, and K. V. Shah. 1995. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J. Natl. Cancer Inst. 87:796-802.
4. Brett, S. J., L. Dunlop, F. Y. Liew, and J. P. Tite. 1993. Influence of the antigen delivery system on immunoglobulin isotype selection and cytokine production in response to influenza A nucleoprotein. Immunology 80:306-312.
5. Cardenas, L., U. Dasgupta, and J. D. Clements. 1994. Influence of strain viability and antigen dose on the use of attenuated mutants of Salmonella as vaccine carriers. Vaccine 12:833-840.
6. Christensen, N. D., J. Dillner, C. Eklund, J. J. Carter, G. C. Wipf, C. A. Reed, N. M. Cladel, and D. A. Galloway. 1996. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 223:174-184.
7. Curtiss, R., III. 1990. Attenuated Salmonella strains as live vectors for the expression of foreign antigens, p. 161-188. In G. C. Woodrow and M. M. Levine (ed.), New generation vaccines. Marcel Dekker, Inc., New York, N.Y.
8. Curtiss, R., III, J. O. Hassan, J. Herr, S. M. Kelly, M. Levine, G. G. Mahairas, D. Milich, D. Peterson, F. Schödel, J. Srinivasan, C. Tacket, S. A. Tinge, and R. Wright. 1994. Nonrecombinant and recombinant avirulent Salmonella vaccines, p. 340-351. In G. P. E. A. Talwar (ed.), Recombinant and synthetic vaccines. Narosa Publishing House, New Delhi, India.
9. Curtiss, R., III, and S. M. Kelly. 1987. Salmonella typhimurium deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic. Infect. Immun. 55:3035-3043.
10. Curtiss, R., III, S. M. Kelly, S. A. Tinge, C. O. Tacket, M. M. Livine, J. Srinivasan, and M. Koopman. 1994. Recombinant Salmonella vectors in vaccine development, p. 23-33. In F. Brown (ed.), Recombinant vectors in vaccine development, vol. 82. Karger, Basel, Switzerland.
11. Dougan, G., S. Chatfield, D. Pickard, J. Bester, D. O'Callaghan, and D. Maskell. 1988. Construction and characterization of vaccine strains of Salmonella harboring mutations in two different aro genes. J. Infect. Dis. 158: 1329-1335.
12. Dunstan, S. J., C. P. Simmons, and R. A. Strugnell. 1998. Comparison of the abilities of different attenuated Salmonella typhimurium strains to elicit humoral immune responses against a heterologous antigen. Infect. Immun. 66:732-740.
13. Fields, P. I., E. A. Groisman, and F. Heffron. 1989. A Salmonella locus that controls resistance to microbiocidal proteins from phagocytic cells. Science 243:1059-1062.
14. Fields, P. I., R. V. Swanson, C. G. Haidaris, and F. Heffron. 1986 Mutants of Salmonella typhimurium that cannot survive within the macrophage are avirulent, Proc. Natl. Acad. Sci. USA 83:5189-5193.
15. Galán, J. E., and R. Curtiss III. 1989. Virulence and vaccine potential of pnoP mutants of Salmonella typhimurium. Microb. Pathog. 6:433-443.
16. 2+ as an extracellular signal: environmental regulation of Salmonella virulence. Cell 84:165-174.
17. Groisman, E. A., E. Chiao, C. J. Lipps, and F. Heffron. 1989. Salmonella typhimurium phoP virulence gene is a transcriptional regulator. Proc. Nat. Acad. Sci. USA 86:7077-7081.
18. Gunn, J. S., E. L. Hohmann, and S. I. Miller. 1996. Transcriptional regulation of Salmonella virulence: a PhoQ periplasmic domain mutation results in increased net phosphotransfer to PhoP. J. Bacteriol. 178:6369-6373.
19. Guo, L., K. B. Lim, J. S. Gunn, B. Bainbridge, R. P. Darveau, M. Hackett, and S. I. Miller. 1997. Regulation of lipid A modifications by salmonella typhimurium virulence genes phop-phoq. Science 276:250-253.
20. Hohmann, E. L., C. A. Oletta, K. P. Killeen, and S. I. Miller. 1996. Phop/ phoq-deleted salmonella typhi (ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J. Infect. Dis. 173:1408-1414.
21. Hoiseth, S. K., and B. A. Stocker. 1981. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature 291:238-239.
22. Hopkins, S., J.-P. Kraehenbuhl, F. Schödel, A. Potts, D. Peterson, P. De Grandi, and D. Nardelli-Haefliger. 1995. A recombinant Salmonella typhimurium vaccine induces local immunity by four different routes of immunization. Infect. Immun. 63:3279-3286.
23. Hopkins, S., et al. Submitted for publication.
24. Kelly, S. M., B. A. Bosecker, and R. Curtiss III. 1992. Characterization and protective properties of attenuated mutants of Salmonella choleraesuis. Infect. Immun. 60:4881-4890.
25. Kirnbauer, R., J. Taub, H. Greenstone, R. Roden, M. Durst, L. Gissmann, D. R. Lowy, and J. T. Schiller. 1993. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J. Virol. 67:6929-6936.
26. Miller, I., D. Maskell, C. Hormaeche, K. Johnson, D. Pickard, and G. Dougan. 1989. Isolation of orally attenuated Salmonella typhimurium following TnphoA mutagenesis. Infect. Immun. 57:2758-2763.
27. Miller, S. I., A. M. Kukral, and J. J. Mekalanos. 1989. A two-component regulatory system (phoP phoQ) controls Salmonella typhimurium virulence. Proc. Natl. Acad. Sci. USA 86:5054-5058.
28. Miller, S. I., W. P. Loomis, C. Alpuche-Aranda, I. Behlau, and E. Hoffman. The PhoP virulence regulon and live oral Salmonella vaccines. Vaccine 11:122-125.
29. Miller, S. I., and J. J. Mekalanos. 1990. Constitutive expression of the PhoP regulon attenuates Salmonella virulence and survival within macrophages. J. Bacteriol. 172:2485-2489.
30. Nardelli-Haefliger, D., J.-P. Kraehenbuhl, R. Curtiss III, F. Schödel, A. Potts, S. Kelly, and P. De Grandi. 1996. Oral and rectal immunization of adult female volunteers with a recombinant attenuated Salmonella typhi vaccine strain. Infect. Immun. 64:5219-5224.
31. Nardelli-Haefliger, D., R. B. S. Roden, J. Benyacoub, R. Sahli, J.-P. Kraehenbuhl, J. T. Schiller, P. Lachat, A. Potts, and P. De Grandi. 1997. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect. Immun. 65:3328-3336.
32. Roberts, M., S. N. Chatfield, and G. Dougan. 1994. Salmonella as carriers of heterologous antigens, p. 27-58. CRC Press Inc., Boca Raton, Fla.
33. Schödel, F. 1992. Prospects for oral vaccination using recombinant bacteria expressing viral epitopes. Adv. Virus Res. 41:409-446.
34. Schödel, F., G. Enders, M.-C. Jung, and H. Will. 1990. Recognition of a hepatitis B virus nucleocapsid T-cell epitope expressed as a fusion protein with the subunit B of Escherichia coli heat labile enterotoxin in attenuated salmonellae. Vaccine 8:569-572.
35. Schödel, F., S. M. Kelly, D. L. Peterson, D. R. Milich, and R. Curtiss III. 1994. Hybrid hepatitis B virus core-pre-S proteins synthesized in avirulent Salmonella typhimurium and Salmonella typhi for oral vaccination. Infect. Immun. 62:1669-1676.
36. Srinivasan, J., A. Nayad, and R. Curtiss III. 1995. Effect of the route of immunization using recombinant Salmonella on mucosal and humoral immune responses. Vaccines 95. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
37. Srinivasan, J., S. Tinge, R. Wright, J. C. Herr, and R. Curtiss III. 1995. Oral immunization with attenuated salmonella expressing human sperm antigen induces antibodies in serum and the reproductive tract. Biol. Reprod. 53: 462-471.
38. Svensson, M., B. Stockinger, and M. J. Wick. 1997. Bone marrow-derived dendritic cells can process bacteria for mhc-i and mhc-ii presentation to t cells. J. Immunol. 158:4229-4236.
39. Tacket, C. O., D. M. Hone, G. A. Losonsky, L. Guers, R. Edelman, and M. M. Levine. 1992. Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain. Vaccine 10:443-446.
40. Tacket, C. O., S. M. Kelly, F. Schödel, G. Losonsky, J. P. Nataro, R. Edelman, M. M. Levine, and R. Curtiss III. 1997. Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system. Infect. Immun. 65:3381-3385.
41. Thatte, J., S. Rath, and V. Bal. 1993. Immunization with live versus killed Salmonella typhimurium leads to the generation of an IFN-gamma-dominant versus an IL-4-dominant immune response. Int. Immunol. 5:1431-1436.
42. Vancott, J. L., H. F. Staats, D. W. Pascual, M. Roberts, S. N. Chatfield, M. Yamamoto, M. Coste, P. B. Carter, H. Kiyono, and J. R. McGhee. 1996. Regulation of mucosal and systemic antibody responses by t helper cell subsets, macrophages, and derived cytokines following oral immunization with live recombinant salmonella. J. Immunol. 156:1504-1514.
43. Walker, R. I. 1994. New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine 12:387-400.
44. Wick, M. J. 1995. The phoP locus influences processing and presentation of Salmonella typhimurium antigens by activated macrophages. Mol. Microbiol. 16:465-476.
45. Yang, D. M., N. Fairweather, L. L. Button, W. R. McMaster, L. P. Kahl, and F. Y. Liew. 1990. Oral Salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis. J. Immunol. 7:2281-2285.
46. Zhang, X., S. M. Kelly, W. S. Bollen, and R. Curtiss III. 1997. Characterization and immunogenicity of Salmonella typhimurium SL1344 and UK-1 Δcrp and Δcdt deletion mutants. Infect. Immun. 65:5381-5387.